Philip Morris Reverses Guidance Cut, Raises 2026 Full‑Year Adjusted EPS Forecast Amid ZYN Momentum

Philip Morris International (NYSE: PM) this past week reinstated confidence in its earnings outlook by raising its adjusted full‑year 2026 diluted earnings‑per‑share guidance to between $8.35 and $8.50, reversing the downgrade it issued in July.

The company had previously cut its guidance on July 22—lowering the range to $7.19–$7.34—from an earlier projection of approximately $8.31–$8.46. This week’s upward revision reflects a material improvement in expectations. The details of this move were highlighted by Wiseek.ai, citing the updated guidance during Philip Morris’s participation in the 2026 Barclays Global Consumer Conference.

This latest guidance adjustment comes after Philip Morris reported its second‑quarter and first‑half 2026 results on July 22. At the time, second‑quarter reported diluted EPS declined 7.7% to $1.80, but adjusted diluted EPS rose 15.2% (13.6% excluding a favorable currency impact) to $2.20. The quarter also saw net revenues exceed $11 billion, driven by double‑digit organic growth in both the smoke‑free and combustible segments. The smoke‑free business accounted for approximately 42% of total net revenues, up from the prior year, continuing its strong momentum.

This move sends a clear signal to investors that Philip Morris sees sustained strength in its smoke‑free portfolio, particularly as demand for ZYN nicotine pouches continues to grow. While the exact catalysts were not detailed, the shift in guidance likely reflects confidence in scaling these newer product categories amid evolving regulatory approval and consumer trends.

The stock reaction was not immediately specified, but such a substantial upward revision often enhances investor sentiment, especially for a company navigating a transition from traditional tobacco to smoke‑free alternatives.

Why This Matters

This guidance reversal reflects a notable turnaround in Philip Morris’s outlook. Investors had reacted to the July guidance cut with caution, but the restoration to a higher range reinforces belief in the company’s strategic direction and operational execution.

Key factors underpinning the stronger outlook include:

• Continued growth in the smoke‑free portfolio, as seen in Q2 results.
• Potential upside from ZYN nicotine pouches, which are gaining traction globally.
• Improved financial performance driven by favorable pricing, scale benefits, and product mix.

Looking ahead, investors will likely watch for further updates on regulatory approvals, especially for ZYN packaging or claims, and additional earnings results to confirm whether this guidance upgrade reflects a durable trend.

In sum, Philip Morris’s upgraded EPS guidance underscores renewed optimism in its capacity to deliver earnings growth amid a broader industry shift toward smoke‑free alternatives.